Bioinformatics USA | Kisaco Research

Systems infrastructure, data management and machine learning for life sciences and healthcare informatics labs

Download Agenda
Boston, USA
7-9 May, 2019

Join us for the pre-conference Machine Learning Infrastructure Day on May 7th 2019, taking participants beyond the “what if” and exploring how AI and other advanced analytic tools are being used today. Hear from Eli Lilly, Pfizer, Boehringer Ingelheim and many more.

Why Attend

The volume of biological data available to drug companies today requires increasingly sophisticated tools for storage, sharing and analysis. Machine learning, cloud, data commons and quantum computing all offer important discovery prospects for in silico units. But they also present problems such as build vs buy debate, overcoming cultural differences between biologists and data scientists, standardization and interoperability challenges.

At the Bioinformatics Infrastructure Congress where IT and computational biology heads from pharma, biotech and academia explore how to implement new tools and optimize data storage, security, visualization and analysis. Explore in silico discovery infrastructure and best practice data management for life science and healthcare professionals, including a full day on AI and machine learning. Leave with actionable ideas to improve data management infrastructure, relationships with the best tool providers on the market and insight into how to implement advanced analytics into drug discovery and development.

10 things you will learn...

1. How to facilitate secure data sharing and improve data visualisation, with insight from St Jude Children's Research Hospital and Verge Genomics

2. Making the business case for building vs buying bioinformatics infrastructure

3. How the likes of Pfizer and Boehringer Ingelheim are using machine learning to actively improve real world outcomes

4. How GSK's John Baldoni and the Broad Institute's Anthony Philippakis developed state-of-the-art in silico workforce and workflow

5. How to integrate data at high volumes so that it is still usable within an organization

6. How to improve the quality, aggregation and visualization of multi-dimensional data sets

7. Insight from the University of Chicago’s Robert Grossman on developing a data commons for large biomedical datasets spanning analysis to deep learning

8. Update from the NIH’s Vivien Bonazzi on the Data Commons Pilot to improve data standardization and interoperability

9. How IBM and Sage Bionetworks are using crowd wisdom for the development and improvement of algorithms

10. How to address bottlenecks in data collection and standardization when programming AI platforms, from Eli Lilly, Cloud Pharmaceuticals and Recursion Pharmaceuticals

Who Will Be There

20%
Healthcare informatics professionals
20%
Big pharma
20%
Data-driven biotechs
15%
Data management platforms
15%
Cloud and Saas providers
10%
Systems integrators and consultants

Healthcare informatics professionals

Big pharma

Data-driven biotechs

Data management platforms

Cloud and Saas providers

Systems integrators and consultants

The Speakers

 

Dr Anthony Philippakis M.D., Ph.D.

Venture Partner
Google Ventures

Anthony Philippakis is the Chief Data Officer of the Broad Institute of MIT and Harvard, where he is also an institute scientist.

Dr Anthony Philippakis M.D., Ph.D.

Venture Partner
Google Ventures

Anthony Philippakis is the Chief Data Officer of the Broad Institute of MIT and Harvard, where he is also an institute scientist.

Philippakis is committed to bridging the gap between data sciences and medicine. He is a cardiologist at Brigham and Women’s Hospital, where his primary focus is caring for patients with rare genetic cardiovascular diseases. At the Broad Institute he directs the Data Sciences Platform, an organization of over 100 software engineers and computational biologists that develops software for analyzing genomic and clinical data. In addition to his roles at the Broad Institute and Brigham and Women’s Hospital, Philippakis is a Venture Partner at GV, focusing on machine learning, distributed computing, and genomics.

Philippakis received his M.D. from Harvard Medical School and completed a Ph.D. in biophysics at Harvard. As an undergraduate, he studied mathematics at Yale University, and later completed the Part III (equivalent to M.Phil) in mathematics at Cambridge University. 

 

Dr Kelly Zou

Vice President, Head of Medical Analytics and Insights, R&D and Medical, Upjohn Division
Pfizer

Kelly Zou, Ph.D., PStat® is Vice President, Medical Analytics & Insights, R&D and Medical, Upjohn Division, Pfizer Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously, she was Senior Director, Global Real World Evidence Center of Excellence and Senior Director, Statistical Center for Outcomes, Real World & Aggregate Data at Pfizer. She was Associate Professor of Radiology at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals.

Dr Kelly Zou

Vice President, Head of Medical Analytics and Insights, R&D and Medical, Upjohn Division
Pfizer

Kelly Zou, Ph.D., PStat® is Vice President, Medical Analytics & Insights, R&D and Medical, Upjohn Division, Pfizer Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously, she was Senior Director, Global Real World Evidence Center of Excellence and Senior Director, Statistical Center for Outcomes, Real World & Aggregate Data at Pfizer. She was Associate Professor of Radiology at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals. She was Associate Director of Rates at Barclays Capital. She received both MA and PhD degrees in Statistics from the University of Rochester, following a BA in Mathematics (Summa Cum Laude), with a Minor in Physics. She completed her Postdoctoral Fellowship at Harvard. Her research interests include healthcare policy, big data, and outcomes research, with over 140 professional articles and 4 books. She has played several leadership roles: Chair, Committee of Presidents of Statistical Societies Awards; Chair, Statistical Partnerships among Academe, Industry, and Government Committee, American Statistical Association (ASA); Chair, ASA Health Care Policy Statistics Section; Vice Chair, ASA Committee on Applied Statisticians; Member, Board of Directors and Publications Committee, International Chinese Statistical Association. She was featured as an Outstanding Woman in Data Analytics by Forbes, an Inspirational Women in Statistics & Data Science by Wiley and the Royal Statistical Society, and an Accomplished Woman in Statistics and Data Science by the ASA.

 

Dr Victoria Gamerman

Head of US Informatics and Health Analytics
Boehringer Ingelheim

Dr Victoria Gamerman

Head of US Informatics and Health Analytics
Boehringer Ingelheim
 

Dr Chip Petricoin

Chief Scientific Officer
Perthera

Dr. Emanuel F Petricoin is the Chief Science Officer and Co-Founder of Perthera, Inc., Perthera is a leading precision medicine company that empowers all cancer patients and oncologists globally with the most comprehensive molecular profiling and data analytics process. Dr. Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University since 2005, where he is a University Professor.

Dr Chip Petricoin

Chief Scientific Officer
Perthera

Dr. Emanuel F Petricoin is the Chief Science Officer and Co-Founder of Perthera, Inc., Perthera is a leading precision medicine company that empowers all cancer patients and oncologists globally with the most comprehensive molecular profiling and data analytics process. Dr. Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. He has authored over 400 peer-reviewed publications and invited reviews with an H Factor of 98, and is on the editorial board of over 10 high impact journals. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Nature Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is a Kentucky Colonel.

 

Dr Shahar Keinan

Chief Scientific Officer
Cloud Pharmaceuticals

Dr. Shahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D.

Dr Shahar Keinan

Chief Scientific Officer
Cloud Pharmaceuticals

Dr. Shahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D. in theoretical chemistry from The Hebrew University of Jerusalem and has numerous papers and presentations in the fields of in-silico drug design and discovery, as well as molecular materials design and computational methods development. She has been instrumental in the development of Cloud Pharmaceuticals’ novel Quantum Molecular Design process since its inception at Duke University.

 

Dr Gustavo Stolovitzky

Program Director, Translational Systems Biology and Nanobiotechnology
Thomas J. Watson Research Center

Dr Gustavo Stolovitzky

Program Director, Translational Systems Biology and Nanobiotechnology
Thomas J. Watson Research Center
 

Prof Robert L Grossman

Chief Research Informatics Officer, Division of the Biological Sciences
University of Chicago

Prof Robert L Grossman

Chief Research Informatics Officer, Division of the Biological Sciences
University of Chicago
 

Peter Goodhand

Chief Executive Officer
GA4GH

Peter Goodhand is a leader in the global health sector as a senior executive and board member.

 

Goodhand played a key role in the creation of the Global Alliance for Genomics and Health (GA4GH) and was appointed as its founding Executive Director in 2014, and as Chief Executive Officer in 2018. From May 2016 to April 2018, he also served as the President of the Ontario Institute for Cancer Research (OICR).

Peter Goodhand

Chief Executive Officer
GA4GH

Peter Goodhand is a leader in the global health sector as a senior executive and board member.

 

Goodhand played a key role in the creation of the Global Alliance for Genomics and Health (GA4GH) and was appointed as its founding Executive Director in 2014, and as Chief Executive Officer in 2018. From May 2016 to April 2018, he also served as the President of the Ontario Institute for Cancer Research (OICR).

Prior to the GA4GH and OICR, he was the President and Chief Executive Officer of the Canadian Cancer Society, Canada's largest health charity. Before joining the charitable sector, Goodhand had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson; Board Chair and President of Canada’s Medical Device Industry association (MEDEC); and as the founding Managing Director and then Board Chair of the Health Technology Exchange (HTX).

Goodhand is currently a member of the Occupational Cancer Research Centre Steering Committee, Co-chair of the Medical and Scientific Advisory Board of Global Genes, Co-chair of the International 100K+ Cohorts Consortium (IHCC), and a member of the of the Global Genomic Medicine Collaboration (G2MC) Steering Committee.

He chaired the Government of Canada’s Expert working group on the future of medical isotope production, and was a member of the Canadian delegation to the UN summit on non-communicable diseases.

 

Mike Kellen

Chief Technical Officer
Sage Bionetworks

Mike Kellen

Chief Technical Officer
Sage Bionetworks
 

Mason Victors

Chief Technology Officer
Recursion Pharmaceuticals

Mason earned his MS in Mathematics from BYU, where he focused on developing new approaches to identifying individuals at-risk for chronic kidney disease. After an internship with the NSA, being unable to decide between becoming a spook or pursuing a PhD he chose the obvious route: join a start-up instead. As part of a small team of data scientists at Red Brain Labs and later Savvysherpa, he developed algorithms to mine unstructured medical records, analyze human behavior through cell phone logs, and simulate complex call centers.

Mason Victors

Chief Technology Officer
Recursion Pharmaceuticals

Mason earned his MS in Mathematics from BYU, where he focused on developing new approaches to identifying individuals at-risk for chronic kidney disease. After an internship with the NSA, being unable to decide between becoming a spook or pursuing a PhD he chose the obvious route: join a start-up instead. As part of a small team of data scientists at Red Brain Labs and later Savvysherpa, he developed algorithms to mine unstructured medical records, analyze human behavior through cell phone logs, and simulate complex call centers. Apart from work, he loves spending time with his wife and two daughters.

 

Dr Eric Perakslis

Chief Scientific Officer
Datavant

Eric is currently Chief Science Officer at Datavant, an innovative new company with the mission to organize the worlds healthcare data. Eric is also Visiting Scientist in the Department of Biomedical Informatics at Harvard Medical School and a frequent volunteer advisor to Médecins Sans Frontières and other international aid and relief NGOs.

Dr Eric Perakslis

Chief Scientific Officer
Datavant

Eric is currently Chief Science Officer at Datavant, an innovative new company with the mission to organize the worlds healthcare data. Eric is also Visiting Scientist in the Department of Biomedical Informatics at Harvard Medical School and a frequent volunteer advisor to Médecins Sans Frontières and other international aid and relief NGOs. Most recently Eric was Senior Vice President and Head of the Takeda R&D Data Science Institute where he built an integrated institute of more than 165 multi-disciplinary data scientists serving all aspects of biopharmaceutical R&D and digital health. Prior to Takeda, Eric was the Executive Director of the Center for Biomedical Informatics and the Countway Library of Medicine, an Instructor in Pediatrics at Harvard Medical School and a faculty member of the Children’s Hospital Informatics Program at Boston Children’ Hospital. Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.ChE and M.S. degrees in chemical engineering.

 

Dr Stacie Calad-Thomson

Chief Operating Officer
ATOM Consortium

Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco.

Dr Stacie Calad-Thomson

Chief Operating Officer
ATOM Consortium

Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. The goal of the consortium is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. Stacie has worked for GSK, starting as a chemist and moving into business strategy and operations roles within R&D Platform Technology & Sciences, where she led several change initiatives. She has a BS (UC Berkeley) and a PhD (UC Irvine) in chemistry.

 

Matthew Trunnell

Vice President and Chief Data Officer
Fred Hutchinson Cancer Research Center

Matthew Trunnell

Vice President and Chief Data Officer
Fred Hutchinson Cancer Research Center
 

Dr Will Salerno

Head of Data Production and Genome Informatics
Regeneron Pharmaceuticals

Dr Will Salerno

Head of Data Production and Genome Informatics
Regeneron Pharmaceuticals
 

Dr Nils Gehlenborg

Assistant Professor of Bioinformatics
Harvard Medical School

Dr Nils Gehlenborg

Assistant Professor of Bioinformatics
Harvard Medical School
 

Anita de Waard

Vice President, Research Collaborations
Elsevier

Anita de Waard

Vice President, Research Collaborations
Elsevier
 

Jim Brase

Deputy Associate Director for Data Science
Lawrence Livermore National Laboratory

Jim Brase

Deputy Associate Director for Data Science
Lawrence Livermore National Laboratory

The Agenda

Download the agenda for Bioinformatics Infrastructure USA

Watch highlights from the AI Hardware Summit 2018

 

Register your interest

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Platinum Partner

Media Partners

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.

Venue

Hyatt Regency Boston Harbor, Boston, MA

Venue: Hyatt Regency Boston Harbor
Address: 101 Harborside Drive, Boston, MA 02128

Room rate: $349 exclusive of applicable taxes, double for single occupancy

To make your reservation, please click here: https://www.hyatt.com/en-US/group-booking/BOSHA/G-05KO or call the Hotel Reservation Department on +1 877 803 7534 quoting Kisaco Research Bioinformatics Infrastructure USA. Click here to find contact information by Region.

Book by 7th April 2019 - after this date rates are subject to availability.

If the group rate is no longer available, prevailing rates may be offered for some or all of your dates.

Nearby accommodation:

Embassy Suites Boston at Logan Airport, 207 Porter St. Boston, MA 02128 (5 minute drive from Hyatt Regency Boston Harbor)

Room rate $279 exclusive of applicable taxes, double for single occupancy

Book online at: https://embassysuites.hilton.com/en/es/groups/personalized/B/BOSAPES-GA1-20190506/index.jhtml?WT.mc_id=POG

Book by 14th April 2019 - after this date rates are subject to availability

Accessibility:

We are committed to making our event accessible for everyone. If you are traveling for the event, Cloud of Goods provides mobility scooter rentals, wheelchair rentals, and other mobility solutions. They will deliver directly to you at the event, your hotel, the airport, or any other place of your choosing. Event attendees will receive a 20% discount when using the code: RENTGEAR032

Visit: https://www.cloudofgoods.com/ 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Worldpay:
Preparing registration...

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

You may withdraw this consent at any time by emailing us at [email protected].
To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Kisaco Research
Registered office address: The Plaza Unit 2.21, 535 Kings Road, London, England, SW10 0SZ
+44 (0)20 3696 2920 | [email protected]
Place of registration: London, United Kingdom
Company number: 09316521

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.